Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Natco PharmaNSE:NATCOPHARM -1.38%89 PS Ratio is 4.03 as of Aug. 01, 2026, which is 28% below its 10-year median of 5.56. GuruFocus rates NSE:NATCOPHARM with a GF Score™ of 89/100 and a GF Value™ of ₹925.32 (Fairly Valued). The stock has 2 warning signs investors should review. Among 954 Drug Manufacturers companies, Natco Pharma ranks worse than 68.45% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Natco Pharma's share price is ₹917.00.
Natco Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹227.71. Hence, Natco Pharma's PS Ratio for today is 4.03.
The historical rank and industry rank for Natco Pharma's PS Ratio or its related term are showing as below:
NSE:NATCOPHARM'
s PS Ratio Range Over the Past 10 Years
Min: 3.14 Med: 5.56 Max: 14.86
Current: 4.04
During the past 13 years, Natco Pharma's highest PS Ratio was 14.86. The lowest was 3.14. And the median was 5.56.
NSE:NATCOPHARM's PS Ratio is ranked worse than 68.45% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs NSE:NATCOPHARM: 4.04
Natco Pharma Ltd revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Natco Pharma was -7.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 15.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 23.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 11.50% per year.
During the past 13 years, Natco Pharma's highest 3-Year average Revenue per Share Growth Rate was 35.60% per year. The lowest was -8.60% per year. And the median was 14.50% per year.
Natco Pharma (NSE:NATCOPHARM) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Natco Pharma PS Ratio Related Terms
Natco Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Natco Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Natco Pharma PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Natco Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Natco Pharma's PS Ratio for today is calculated as
Natco Pharma's Share Price of today is ₹917.00. Natco Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹227.71.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Natco Pharma (NSE:NATCOPHARM) has a PS Ratio of 4.03 as of Aug. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Natco Pharma and its competitors. This is 28% below median its historical median of 5.56. Over the past decade, Natco Pharma's PS Ratio has ranged from 3.14 to 14.86. According to the industry distribution chart, Natco Pharma ranks #653 out of 954 companies in the Drug Manufacturers industry, placing it in the top 68.4%.
Is Natco Pharma's PS Ratio too high?
Natco Pharma's current PS Ratio of 4.03 is 28% below median its 10-year median of 5.56. Over the past 10 years, this metric has ranged from a low of 3.14 to a high of 14.86. The Drug Manufacturers industry median PS Ratio is 2.28. Natco Pharma's value of 4.03 is 76.8% above this industry median. Based on the distribution chart, Natco Pharma ranks #653 out of 954 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Natco Pharma has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Natco Pharma's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Natco Pharma ranks #653 out of 954 companies for PS Ratio. This places Natco Pharma in the lower half of its industry. The industry median PS Ratio is 2.28. Natco Pharma's value of 4.03 is 76.8% above this benchmark. Historically, Natco Pharma's own PS Ratio has ranged from 3.14 to 14.86 over the past decade. While the company's 10-year median is 5.56 vs. the industry median of 2.28, Natco Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.28, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Natco Pharma's current PS Ratio of 4.03 is 76.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Natco Pharma and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Natco Pharma's current PS Ratio is 4.03, which is 28% below median its own 10-year median of 5.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Natco Pharma stock overvalued right now?
Based on GuruFocus' analysis, Natco Pharma (NSE:NATCOPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹925.32, compared to a current price of ₹917.00 — trading 0.9% below its estimated fair value. The current PS Ratio is 4.03, which is 28% below median its 10-year median of 5.56 and 76.8% above the Drug Manufacturers industry median of 2.28. Natco Pharma's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Natco Pharma (NSE:NATCOPHARM), the current PS Ratio is 4.03 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Natco Pharma (NSE:NATCOPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Natco Pharma stock appears to be undervalued.
The current stock price of ₹917.00 is trading 0.9% below its estimated GF Value™ of ₹925.32.
GuruFocus considers Natco Pharma to be Fairly Valued.
Key valuation signals for NSE:NATCOPHARM:
PS Ratio: 4.03 (28% below median its 10-year median of 5.56)
GF Value™: ₹925.32 vs. price of ₹917.00 (0.9% below fair value)
Industry Position: 76.8% above the Drug Manufacturers median (#653 of 954)
No single metric tells the full story. See the NSE:NATCOPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
89GF Score
Get the complete analysis for NSE:NATCOPHARM
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NATCOPHARM has been successfully added to your 
